Cellular uptake of PLGA nanoparticles targeted with anti-amyloid and anti-transferrin receptor antibodies for Alzheimer’s disease treatment

Loureiro, Joana A.; Gomes, Bárbara; Fricker, Gert; Coelho, Manuel A. N.; Rocha, Sandra; Pereira, Maria do Carmo

doi:10.1016/j.colsurfb.2016.04.041

Cited by 152 publications

(70 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Usually, drug-loaded NPs exert therapeutic effects on cancer cells depending on internalization and sustained retention 45. In vitro investigation provides indirect evidence for verifying the advantages of nanoformulation in comparison with free anticancer drug, although it is different from in vivo bioprocess.…”

Section: Resultsmentioning

confidence: 99%

Paclitaxel-loaded star-shaped copolymer nanoparticles for enhanced malignant melanoma chemotherapy against multidrug resistance

Su¹,

Hu²,

Huang³

et al. 2017

DDDT

View full text Add to dashboard Cite

Malignant melanoma (MM) is the most dangerous type of skin cancer with annually increasing incidence and death rates. However, chemotherapy for MM is restricted by low topical drug concentration and multidrug resistance. In order to surmount the limitation and to enhance the therapeutic effect on MM, a new nanoformulation of paclitaxel (PTX)-loaded cholic acid (CA)-functionalized star-shaped poly(lactide-co-glycolide) (PLGA)-D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS) nanoparticles (NPs) (shortly PTX-loaded CA-PLGA-TPGS NPs) was fabricated by a modified method of nanoprecipitation. The particle size, zeta potential, morphology, drug release profile, drug encapsulation efficiency, and loading content of PTX-loaded NPs were detected. As shown by confocal laser scanning, NPs loaded with coumarin-6 were internalized by human melanoma cell line A875. The cellular uptake efficiency of CA-PLGA-TPGS NPs was higher than those of PLGA NPs and PLGA-TPGS NPs. The antitumor effects of PTX-loaded NPs were evaluated by the MTT assay in vitro and by a xenograft tumor model in vivo, demonstrating that star-shaped PTX-loaded CA-PLGA-TPGS NPs were significantly superior to commercial PTX formulation Taxol®. Such drug delivery nanocarriers are potentially applicable to the improvement of clinical MM therapy.

show abstract

Section: Resultsmentioning

confidence: 99%

Paclitaxel-loaded star-shaped copolymer nanoparticles for enhanced malignant melanoma chemotherapy against multidrug resistance

Su¹,

Hu²,

Huang³

et al. 2017

DDDT

View full text Add to dashboard Cite

show abstract

“…The results showed that for long-term circulation without any surface modification, the 100 nm nanoparticles worked best because they could escape the liver metabolism (107). This and several other studies suggest that PLGA is a promising candidate for enhancing therapeutic delivery into the CNS (108)(109)(110)(111)(112)(113)(114)(115)(116)(117)(118)(119)(120). However, PLGA degrades by bulk erosion, which can lead to premature exposure of the therapeutic to a degradative environment.…”

mentioning

confidence: 76%

Treatment of neurodegenerative disorders through the blood–brain barrier using nanocarriers

et al. 2018

View full text Add to dashboard Cite

Neurodegenerative diseases refer to disorders of the central nervous system (CNS) that are caused by neuronal degradations, dysfunctions, or death. Alzheimer's disease, Parkinson's disease, and Huntington's disease (APHD) are regarded as the three major neurodegenerative diseases. There is a vast body of literature on the causes and treatments of these neurodegenerative diseases. However, the main obstacle in developing an effective treatment strategy is the permeability of the treatment components at the blood-brain barrier (BBB). Several strategies have been developed to improve this obstruction. For example, nanomaterials facilitate drug delivery to the BBB due to their size. They have been used widely in nanomedicine and as nanoprobes for diagnosis purposes among others in neuroscience. Nanomaterials in different forms, such as nanoparticles, nanoemulsions, solid lipid nanoparticles (SLN), and liposomes, have been used to treat neurodegenerative diseases. This review will cover the basic concepts and applications of nanomaterials in the therapy of APHD.

show abstract

“…The brain penetration of fluorescent tagged PLGA NPs engineered with two different moieties (pep‐apoE or l ‐PGDS) was here investigated in vivo with different techniques. Other functionalization ligands have been previously tested in in vitro models of BBB to assess the passage across the endhotelial cells, or in vivo for brain targeting of PLGA NPs. A sequence derived from leptin or a similar opioid glycopeptide (NPs around 200 nm in size) have been used to functionalize fluorescent PLGA NPs and functional (anorectic and nociceptive) effects were assessed in rats up to 2 h after iv injection.…”

Section: Discussionmentioning

confidence: 99%

Novel functionalization strategies of polymeric nanoparticles as carriers for brain medications

Portioli

Bovi

Benati

et al. 2016

J Biomedical Materials Res

View full text Add to dashboard Cite

For targeted brain delivery, nanoparticles (NPs) should bypass the blood-brain barrier (BBB). Novel functionalization strategies, based on low-density lipoprotein receptor (LDLR) binding domain, have been here tested to increase the brain targeting efficacy of poly d,l-lactic-co-glycolic acid (PLGA) NPs, biodegradable and suited for biomedical applications. Custom-made PLGA NPs were functionalized with an apolipoprotein E modified peptide (pep-apoE) responsible for LDLR binding, or with lipocalin-type prostaglandin-d-synthase (L-PGDS), highly expressed in the brain. At the comparison of pep-apoE and L-PGDS sequences, a highly homologs region was here identified, indicating that also L-PGDS could bind LDLR. Non-functionalized and functionalized NPs did not affect the viability of cultured human dendritic cells, protagonists of the immune response, and did not activate them to a proinflammatory profile. At 2 h after intravenous injection in mice, functionalized, but not the non-functionalized ones, fluorescent-tagged NPs were observed in the cerebral cortex parenchyma. The NPs were mostly internalized by neurons and microglia; glial cells showed a weak activation. The findings indicate that the tested functionalization strategies do not elicit adverse immune responses and that the peptidic moieties enable BBB traversal of the NPs, thus providing potential brain drug carriers. These could be especially effective for brain diseases in which LDLR is involved. © 2016 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 105A: 847-858, 2017.

show abstract

Cellular uptake of PLGA nanoparticles targeted with anti-amyloid and anti-transferrin receptor antibodies for Alzheimer’s disease treatment

Cited by 152 publications

References 52 publications

Paclitaxel-loaded star-shaped copolymer nanoparticles for enhanced malignant melanoma chemotherapy against multidrug resistance

Paclitaxel-loaded star-shaped copolymer nanoparticles for enhanced malignant melanoma chemotherapy against multidrug resistance

Treatment of neurodegenerative disorders through the blood–brain barrier using nanocarriers

Novel functionalization strategies of polymeric nanoparticles as carriers for brain medications

Contact Info

Product

Resources

About